The short version of REV-ERB agonist fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-01-28. Anything still debated is marked as such rather than presented as settled.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ in preclinical models |
| Molecular formula | C20H24ClN3O4S | Reported for the parent compound |
| CAS Registry Number | 1379686-30-2 | Common identifier in chemical databases |
| Appearance | Off-white to pale yellow solid | Typical research chemical solid |
| Solubility | Soluble in DMSO and ethanol; low in water | Class: small organic molecule |
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
On September 9, 2025, Talarico announced his candidacy for the 2026 U.S. Senate election in Texas. He and U.S. Representative Jasmine Crockett vied for the Democratic nomination. In February 2026, the Houston Chronicle, the Austin American-Statesman, The Dallas Morning News, and the Fort Worth Star-Telegram endorsed Talarico. Later in February, the FCC opened an investigation into Talarico's appearance on The View, citing a potential violation of the equal-time rule. Late-night and talk shows were exempt from the requirement until an FCC rule change in January 2026. On February 16, 2026, Talarico was scheduled to appear on The Late Show with Stephen Colbert. Colbert said CBS canceled the interview because of the Trump administration's "intensifying pressure against broadcast TV networks". He said the network's lawyers had instructed him not to have Talarico on the show or mention the cancellation. Against their advice, he interviewed Talarico and spoke publicly about the cancellation. Colbert accused CBS of censorship and posted the interview to the show's YouTube page instead, where it had gained 7.3 million views by February 18, making it the most viewed interview segment on The Late Show's channel in a year. On March 3, Talarico won the Democratic primary, securing the party's nomination in the November general election. In the general election, he faces Texas Attorney General Ken Paxton, who won the Republican primary runoff on May 26. Former President Barack Obama appeared at an event with Talarico in May 2026.
Deborah Ann Dingell ( DING-gəl; née Insley; November 23, 1953) is an American politician serving as a U.S. representative from Michigan since 2015, representing the state's 6th congressional district since 2023. A member of the Democratic Party, she succeeded her late husband, John Dingell, who was the longest-serving member of Congress in U.S. history. Dingell is active in several organizations in Michigan and Washington, D.C., and serves on a number of boards. She is a founder and past chair of the National Women's Health Resource Center and the Children's Inn at the National Institutes of Health (NIH). She is also a member of the board of directors for Vital Voices Global Partnership. She is a 1975 graduate of the Edmund A. Walsh School of Foreign Service at Georgetown University. She worked as a consultant to the American Automobile Policy Council. She was a superdelegate for the 2012 Democratic National Convention in Charlotte, North Carolina.
== See also == Allicin, the active piquant flavor chemical in uncooked garlic, and to a lesser extent onions (see those articles for discussion of other chemicals in them relating to pungency, and eye irritation) Capsazepine, capsaicin antagonist Iodoresiniferatoxin, an ultrapotent capsaicin antagonist derived from Resiniferatoxin Naga Viper pepper, Bhut Jolokia Pepper, Carolina Reaper, Trinidad Moruga Scorpion; some of the world's most capsaicin-rich fruits Piperine, the active flavor chemical in black pepper List of capsaicinoids
In April 2023, Monster Beverage Corporation sued independent videogame developer Glowstick Entertainment for their horror party game Dark Deception: Monsters and Mortals. Apparently to Monster Beverage, the use of "Monster" in the title of the game and their green and black logo make it "very confusing" because of the similarities between the two. Glowstick Entertainment's head creator, Vincent Livings, had decided to fight it in court and has since won the case. Additionally later that month, it was discovered that over 100 trademark complaints had been filed in Japan, including complaints against the Pokémon (1996–), Monster Hunter (2004–), and Monster Musume (2012–) franchises, the first of which predates the Monster Energy brand by over half a decade.
Sources: en.wikipedia.org
Phenylglyoxal is the organic compound with the formula C6H5C(O)C(O)H. It contains both an aldehyde and a ketone functional group. It is yellow liquid when anhydrous but readily forms a colorless crystalline hydrate. It has been used as a reagent to modify the amino acid, arginine. It has also been used to attach chemical payload (probes) to the amino acid citrulline and to peptides/proteins.
=== MHC-I === MHC-I heavy chains may work as chaperones with the aid of the calnexin-calreticulin complex in the ER. In addition to this, β2-microglobulin (β2m) is attached to the heavy chains of the heterodimers and as a whole they act as receptors for antigenic peptides. When MHC-I chains are empty, they are recruited by calreticulin and form a transient PLC. Tapasin regularly plays a role in the stabilization of MHC-I. Only after MHC-I heterodimers are deployed for peptide proofreading or editing, stable pMHC-I (peptide-MHC-I) complexes are released to the cell surface for recognition and destruction of virus-infected or malignantly neoplastic cells. In general, each individual organism owns a collection of six MHC-I molecules (three from each parent). Thus, in autoimmune emergencies, compatible donors are relatives who own a similar collection of MHC-I molecules, apart from those of the recipient.
(2008) citing Loureiro and Malfeito-Ferreira from 2006 when they affirmed that current molecular DNA detection techniques have uncovered no variance between the anamorph and teleomorph states. Over the past decade, Brettanomyces spp. have seen an increasing use in the craft-brewing sector of the industry, with a handful of breweries having produced beers that were primarily fermented with pure cultures of Brettanomyces spp. This has occurred out of experimentation, as very little information exists regarding pure culture fermentative capabilities and the aromatic compounds produced by various strains. Dekkera/Brettanomyces spp. have been the subjects of numerous studies conducted over the past century, although a majority of the recent research has focused on enhancing the knowledge of the wine industry. Recent research on eight Brettanomyces strains available in the brewing industry focused on strain-specific fermentations and identified the major compounds produced during pure culture anaerobic fermentation in wort.
Is produced at a distillery in Scotland from water and malted barley (to which only whole grains of other cereals may be added) all of which have been: Processed at that distillery into a mash Converted at that distillery to a fermentable substrate only by endogenous enzyme systems Fermented at that distillery only by adding yeast Has been distilled at an alcoholic strength by volume of less than 94.8% (190 US proof) Is wholly matured in an excise warehouse in Scotland in oak casks of a capacity not exceeding 700 litres (185 US gal; 154 imp gal) for at least three years Retains the colour, aroma, and taste of the raw materials used in, and the method of, its production and maturation Contains no added substances, other than water and plain (E150A) caramel colouring Has a minimum alcoholic strength by volume of 40% (80 US proof) The Scotch Whisky Association acts as the regulatory body that ensures that Scotch Whisky is produced in accordance with traditional practices, as well as ensuring a sustainable future for the Scotch Whisky industry by promoting sustainable production, global trade, and responsible consumption.
Half Bad is a 2014 young adult fantasy novel written by English author Sally Green. It won the 2015 Waterstones Teen Book Prize and was shortlisted for the 2015 Branford Boase Award. On 3 March 2014, the book set the Guinness World Record as the 'Most Translated Book by a Debut Author, Pre-publication', having sold in 45 languages prior to its UK publication by Penguin books.
Sources: en.wikipedia.org
=== 6.5% salt broth === The 6.5% salt broth test is used to analyze the tolerance level of various bacteria under halophilic conditions. This test is used because most organisms cannot survive in high salt concentrations while Staphylococci, Enterococci, and Aerococci are all expected to tolerate 6.5% NaCl concentrations.
One arm lying west of the body, 23 feet long; one stump of arm about 4 feet long; three arms lying south of body and from appearance attached to same (although I did not dig quite to body, as it laid well down in the sand and I was very tired), longest one measured over 23 feet, the other arms were three to five feet shorter. In the first days of December 1896, Dr. George Grant, owner of a hotel at South Beach on Anastasia Island, wrote a short article describing the carcass, which was published in the Pennsylvania Grit of Williamsport on December 13. The article was accompanied by a picture of the "sea monster" depicting a tentacled creature with a tail. This was drawn by the draughtsman of the newspaper based on Grant's description, and not an eyewitness. Grant's description was as follows:
=== Use of blockhouses === The British were forced to revise their tactics. They concentrated on restricting the freedom of movement of the Boer commandos and depriving them of local support. The railway lines had provided vital lines of communication and supply, and as the British had advanced across South Africa, they had used armoured trains and established fortified blockhouses at key points along most lines. They built additional blockhouses (each housing between six to eight soldiers under a non-commissioned officer) at bridges and beside major roads connecting rural towns, and fortified these to protect supply routes against Boer raiders. Eventually over 8,000 such blockhouses were built across the republics, radiating from the larger towns along principal roads and railways. Each blockhouse cost £800-£1,000 and took three months to build. Despite this, they proved effective; not one bridge or any section of railway line at which an occupied blockhouse was blown up. The blockhouse system required many troops to garrison. Well over 50,000 British troops, or 50 battalions, were involved in blockhouse duty, greater than the approximately 30,000 Boers in the field during the guerrilla phase. In addition, up to 16,000 local Africans were used as armed guards and to patrol the line at night. The Army linked the blockhouses with barbed wire fences to parcel up the wide veld into smaller areas.
=== Off-label use === Although rhBMP-2 and rhBMP-7 are used in the treatment of a variety of bone-related conditions including spinal fusions and nonunions, the risks of this off-label treatment are not understood. While rhBMPs are approved for specific applications (spinal lumbar fusions with an anterior approach and tibia nonunions), up to 85% of all BMP usage is off-label. rhBMP-2 is used extensively in other lumbar spinal fusion techniques (e.g., using a posterior approach, anterior or posterior cervical fusions).
In other instances, molecular interactions between gas molecules previously adsorbed on a solid surface form significant interactions with gas molecules in the gaseous phases. Hence, adsorption of gas molecules to the surface is more likely to occur around gas molecules that are already present on the solid surface, rendering the Langmuir adsorption isotherm ineffective for the purposes of modelling. This effect was studied in a system where nitrogen was the adsorbate and tungsten was the adsorbent by Paul Kisliuk (1922–2008) in 1957. To compensate for the increased probability of adsorption occurring around molecules present on the substrate surface, Kisliuk developed the precursor state theory, whereby molecules would enter a precursor state at the interface between the solid adsorbent and adsorbate in the gaseous phase. From here, adsorbate molecules would either adsorb to the adsorbent or desorb into the gaseous phase. The probability of adsorption occurring from the precursor state is dependent on the adsorbate's proximity to other adsorbate molecules that have already been adsorbed. If the adsorbate molecule in the precursor state is in close proximity to an adsorbate molecule that has already formed on the surface, it has a sticking probability reflected by the size of the SE constant and will either be adsorbed from the precursor state at a rate of kEC or will desorb into the gaseous phase at a rate of kES.
Sources: en.wikipedia.org
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.
No. It is a synthetic ligand that binds nuclear receptors, not a steroid or peptide hormone. Its activity depends on receptor binding rather than endocrine secretion.
Clinical evidence is limited. Most published data come from cell and animal experiments. Human safety and efficacy remain uncertain.
It is usually detected by LC-MS or HPLC-UV against a reference standard. In biological matrices, metabolite targeting can improve detection. No universal immunoassay is widely available.